- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
iRhythm Technologies Receives 'Moderate Buy' Rating from Analysts
Analysts see potential in the company's wearable cardiac monitoring devices and data analytics services.
Mar. 15, 2026 at 7:09am by Ben Kaplan
Got story updates? Submit your updates here. ›
iRhythm Technologies (NASDAQ:IRTC) has received a consensus rating of "Moderate Buy" from 15 analysts covering the company. The average 12-month price target is $209.46. Several analysts have issued reports on the company, with Needham & Company reiterating a "buy" rating and $244 price target, and Evercore upgrading the stock to "outperform" and raising the price target to $210.
Why it matters
iRhythm's flagship product, the Zio patch, is a discreet, single-use ECG monitor that can track heart rhythms for up to 14 days. The company's digital diagnostics platform combines biosensor technology and algorithms to detect arrhythmias and streamline data interpretation for physicians. As the cardiac monitoring market continues to evolve, iRhythm's innovative approach could position it for growth.
The details
The analysts' ratings and price targets reflect their views on iRhythm's potential. The company has received a mix of ratings, with one "sell" recommendation, one "hold", eleven "buy", and two "strong buy" recommendations. Analysts cited the company's Zio patch and digital diagnostics platform as key drivers for the positive outlook.
- iRhythm Technologies reported Q4 2025 earnings on February 20, 2026.
The players
iRhythm Technologies
A medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services.
Needham & Company LLC
An investment banking and asset management firm that covers iRhythm Technologies.
Evercore
An independent investment banking advisory firm that covers iRhythm Technologies.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
San Francisco top stories
San Francisco events
Mar. 17, 2026
Joe Klocek & FriendsMar. 17, 2026
Clinton Kane - 4350 Live with Julian Ray




